Blood Exosomal Micro Ribonucleic Acid Profiling Reveals the Complexity of Hepatocellular Carcinoma and Identifies Potential Biomarkers for Differential Diagnosis

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2020 Nov 2

PMID 33133386

Citations 8

Authors

Lang-Qing Sheng

Jia-Rong Li

Hao Qin

Ling Liu

Da-Dong Zhang

Qi Zhang

Meng-Li Huang

Xiao-Li Li

Xiao-Ya Xu

Yang-Nian Wei

Zi-Shuo Chen

Hui Luo

Ji-Yang Zhang

Cheng-Hui Zhou

Hao Chen

Ze-Guo Chen

Fu-Gen Li

Nian-Feng Li

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide, but there is a shortage of effective biomarkers for its diagnosis.

Aim: To explore blood exosomal micro ribonucleic acids (miRNAs) as potential biomarkers for HCC diagnosis.

Methods:

Results: The principal component analysis suggested that daily alcohol consumption could alter the blood exosomal miRNA profiles of hepatitis B virus positive non-HCC patients through miR-3168 and miR-223-3p. The miRNA profiles also revealed the tumor stages of HCC patients. High expression of miR-455-5p and miR-30c-5p, which significantly correlated with better overall survival in tumor tissues, could also be detected in blood exosomes. Two pairs of miRNAs (miR-584-5p/miR-106-3p and miR-628-3p/miR-941) showed a 94.1% sensitivity and 68.4% specificity to differentiate HCC patients from non-HCC patients. The specificity of the combination was substantially influenced by alcohol consumption habits.

Conclusion: This study suggested that blood exosomal miRNAs can be used as new non-invasive diagnostic tools for HCC. However, their accuracy could be affected by tumor stage and alcohol consumption habits.

Citing Articles

Chen L, Wu G, Wu T, Shang H, Wang W, Fisher D Curr Med Sci. 2024; 44(6):1217-1231.

PMID: 39681799 DOI: 10.1007/s11596-024-2924-9.

Insight into the Role of the miR-584 Family in Human Cancers.

Braile M, Luciano N, Carlomagno D, Salvatore G, Orlandella F Int J Mol Sci. 2024; 25(13).

PMID: 39000555 PMC: 11242779. DOI: 10.3390/ijms25137448.

The social and occupational consequences of the COVID-19 pandemic among patients with multiple sclerosis in three distinct populations: A web-based cross-sectional survey.

Zhang G, Zhao R, Zhang W, Yu W, Zhang X, Gao S Neurol Perspect. 2024; 2(1):9-20.

PMID: 38620860 PMC: 8574073. DOI: 10.1016/j.neurop.2021.10.004.

Advances of multi-omics applications in hepatic precancerous lesions and hepatocellular carcinoma: The role of extracellular vesicles.

Lu X, Li Y, Li Y, Zhang X, Shi J, Feng H Front Mol Biosci. 2023; 10:1114594.

PMID: 37006626 PMC: 10060991. DOI: 10.3389/fmolb.2023.1114594.

Circulating exosomal microRNAs as potential prognostic biomarkers in gastrointestinal cancers: a systematic review and meta-analysis.

Gheytanchi E, Tajik F, Razmi M, Babashah S, Cho W, Tanha K Cancer Cell Int. 2023; 23(1):10.

PMID: 36670440 PMC: 9862982. DOI: 10.1186/s12935-023-02851-8.

References

Xu T, Li L, Hu H, Meng X, Huang C, Zhang L . MicroRNAs in alcoholic liver disease: Recent advances and future applications. J Cell Physiol. 2018; 234(1):382-394. DOI: 10.1002/jcp.26938. View

Manri C, Yokoi T, Nishida H . Size-Selective Harvesting of Extracellular Vesicles for Strategic Analyses Towards Tumor Diagnoses. Appl Biochem Biotechnol. 2016; 182(2):609-623. DOI: 10.1007/s12010-016-2348-5. View

Zhu H, Liu R, Liang Y, Hasan A, Wang H, Shao Q . Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver Int. 2017; 37(6):888-896. DOI: 10.1111/liv.13356. View

Griffiths-Jones S, Saini H, van Dongen S, Enright A . miRBase: tools for microRNA genomics. Nucleic Acids Res. 2007; 36(Database issue):D154-8. PMC: 2238936. DOI: 10.1093/nar/gkm952. View

Rocco A, Compare D, Angrisani D, Sanduzzi Zamparelli M, Nardone G . Alcoholic disease: liver and beyond. World J Gastroenterol. 2014; 20(40):14652-9. PMC: 4209531. DOI: 10.3748/wjg.v20.i40.14652. View

Zhou F, Shang W, Yu X, Tian J . Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2017; 38(2):741-767. DOI: 10.1002/med.21455. View

Jeon Y, Jang E, Choi Y, Kim J, Jeong S . Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clin Mol Hepatol. 2016; 22(3):359-365. PMC: 5066378. DOI: 10.3350/cmh.2016.0033. View

Buitrago D, Patnaik S, Kadota K, Kannisto E, Jones D, Adusumilli P . Small RNA sequencing for profiling microRNAs in long-term preserved formalin-fixed and paraffin-embedded non-small cell lung cancer tumor specimens. PLoS One. 2015; 10(3):e0121521. PMC: 4374839. DOI: 10.1371/journal.pone.0121521. View

Peck-Radosavljevic M . Drug therapy for advanced-stage liver cancer. Liver Cancer. 2014; 3(2):125-31. PMC: 4057791. DOI: 10.1159/000343868. View

10.

Sandoval-Borquez A, Polakovicova I, Carrasco-Veliz N, Lobos-Gonzalez L, Riquelme I, Carrasco-Avino G . MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer. Clin Epigenetics. 2017; 9:114. PMC: 5645854. DOI: 10.1186/s13148-017-0413-8. View

11.

Liu X, Cui D, Li Y, Liu Y, Liu G, Liu L . Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis. World J Gastroenterol. 2019; 25(30):4199-4212. PMC: 6700689. DOI: 10.3748/wjg.v25.i30.4199. View

12.

Chen W . Cancer statistics: updated cancer burden in China. Chin J Cancer Res. 2015; 27(1):1. PMC: 4329178. DOI: 10.3978/j.issn.1000-9604.2015.02.07. View

13.

Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z . Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011; 29(36):4781-8. DOI: 10.1200/JCO.2011.38.2697. View

14.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

15.

Banales J, Inarrairaegui M, Arbelaiz A, Milkiewicz P, Muntane J, Munoz-Bellvis L . Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. Hepatology. 2018; 70(2):547-562. PMC: 6767196. DOI: 10.1002/hep.30319. View

16.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

17.

Suetsugu A, Honma K, Saji S, Moriwaki H, Ochiya T, Hoffman R . Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug Deliv Rev. 2012; 65(3):383-90. DOI: 10.1016/j.addr.2012.08.007. View

18.

Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G . A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2017; 67(2):662-675. PMC: 6680350. DOI: 10.1002/hep.29561. View

19.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

20.

Zhao Y, Ju Q, Li G . Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2014; 1(4):593-598. PMC: 3915636. DOI: 10.3892/mco.2013.119. View